Blood test could help personalize breast cancer therapy
NCT ID NCT05977036
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a blood test measuring thymidine kinase activity (TKa) can help doctors decide early if a patient's breast cancer treatment is working. Patients with HR+ HER2- metastatic breast cancer start standard therapy with a CDK4/6 inhibitor and endocrine therapy. If the blood test at day 15 shows the treatment isn't suppressing TKa, patients switch to a different therapy. The goal is to see if this early switch improves how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CDK4/6 inhibitor plus endocrine therapy
What this could lead to
If successful, this could show that a simple blood test helps doctors choose the right treatment earlier, potentially improving how long the cancer is controlled.
What could go wrong
This is a small, early-phase study (65 people) without a control group, so results may not apply broadly. The blood test may not reliably predict treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact